RACHEL GRAVES: Open Payments
NPI 1720668783 · ALLENTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,126 in 52 payments from 12 companies in 2025. Trend: 2023 $24 · 2024 $737 · 2025 $1,126
Food & beverage: $1,126
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $312 |
| CSL Behring | 6 | $157 |
| GENZYME CORPORATION | 5 | $121 |
| Optinose US, Inc. | 4 | $104 |
| BioCryst US Sales Co., LLC | 3 | $84 |
| Amgen Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| Genentech USA, Inc. | 2 | $50 |
Products named: FASENRA, DUPIXENT, Xhance, AIRSUPRA, ORLADEYO, Andembry, TEZSPIRE, NUCALA.
Industry payments across PA — which companies pay providers there.
